Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: liposomal nucleic acid therapeutics - Bio-Path Holdings

Drug Profile

Research programme: liposomal nucleic acid therapeutics - Bio-Path Holdings

Alternative Names: BP-100-1.02; BP-100-2.01; BP-1002; BP-1003; Liposomal Bcl-2; Liposomal Bcl2 antisense; Liposomal FAK; Liposomal Stat3

Latest Information Update: 09 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Bio-Path Holdings
  • Class Antisense RNA; Small interfering RNA
  • Mechanism of Action Focal adhesion protein-tyrosine kinase inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Follicular lymphoma; Pancreatic cancer; Solid tumours

Most Recent Events

  • 27 Dec 2018 Bio-Path announces intention to initiate IND-enabling studies for BP 1003 in Solid tumours (including pancreatic cancer) in USA in 2019
  • 27 Dec 2018 Bio-Path Holdings plans a phase-I trial of BP 1002 for Lymphoma and Chronic lymphocytic leukaemia in 2019
  • 15 Aug 2018 Bio-Path announces intention to submit IND to US FDA for Chronic lymphocytic leukemia in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top